The Epstein-Barr virus early antigen diffuse component (EA-D) is essential for Epstein-Barr virus DNA polymerase activity, and its activity is suppressed during latent infection. We investigated the regulation of the promoter (BMRFl) for this early gene by studying its responsiveness in vitro to two immediate-early viral transactivators, BZLF1 (Z) and BRLF1 (R), focusing on the differences in response in lymphoid cells and epithelial cells. In lymphoid cells, Z or R alone produced only small increases in EA-D promoter activity, whereas both transactivators together produced a large stimulatory effect. In epithelial cells, the Z transactivator alone produced maximal stimulation of the EA-D promoter; the effect of R and Z together was no greater than that of Z alone. Deletional analysis and site-directed mutagenesis of the EA-D promoter demonstrated that in epithelial cells the potential AP-1 binding site plays an essential role in Z responsiveness, although sequences further upstream are also important. In lymphoid cells, only the upstream sequences are required for transactivation by the Z/R combination, and the AP-1 site is dispensable. These data suggest that EA-D (BMRF1) promoter regulation by Z and R is cell type specific and appears to involve different mechanisms in each cell type. (28), raising the question of whether there are different mechanisms for regulation of viral expression in lymphoid and epithelial cells. Overexpression of the immediate-early (IE) EBV gene product, BZLF1, in EBV-infected B cells is sufficient to convert latent expression to productive infection (10, 13, 29, 33) . The BZLF1 gene (Z) encodes a 34-to 38-kilodalton nuclear protein (the Z protein) which has sequence similarity to the DNA-binding site of the c-fos protein and binds to the AP-1 binding site (7) (4, 14, 16, 24, 37) linked to chloramphenicol acetyltransferase (CAT). However, we have shown that the BMLF1 effect is reporter gene dependent and does not result in significantly increased levels of mRNA (14). The role of the BMLF1 gene in induction of lytic viral infection remains unknown.
Epstein-Barr virus (EBV) is a herpesvirus that infects primarily B cells and epithelial cells
. EBV infection of B cells is predominantly latent, whereas epithelial-cell infection is often productive (28) , raising the question of whether there are different mechanisms for regulation of viral expression in lymphoid and epithelial cells. Overexpression of the immediate-early (IE) EBV gene product, BZLF1, in EBV-infected B cells is sufficient to convert latent expression to productive infection (10, 13, 29, 33) . The BZLF1 gene (Z) encodes a 34-to 38-kilodalton nuclear protein (the Z protein) which has sequence similarity to the DNA-binding site of the c-fos protein and binds to the AP-1 binding site (7) , although there is no potential leucine zipper (36) in the Z protein. Exactly how the Z protein binds to the AP-1 site, or whether binding of Z to AP-1 or closely related sites is always required for transactivation of target promoters, is still unknown. Although the Z protein appears to play a key role in determining whether EBV infection is latent or productive, the disruption of latency is likely to involve other EBV transactivators.
Two other EBV IE gene products have been shown to encode transactivator functions. The BMLF1 gene product has been shown by several groups to transactivate a number of homologous and heterologous promoters (4, 14, 16, 24, 37) linked to chloramphenicol acetyltransferase (CAT). However, we have shown that the BMLF1 effect is reporter gene dependent and does not result in significantly increased levels of mRNA (14) . The role of the BMLF1 gene in induction of lytic viral infection remains unknown.
The BRLF1 gene also encodes an IE transactivator function (1, 3, 4, 11, 12) . The BRLF1 gene product is a 94-to 98-kDa protein which localizes to the nucleus and cytoplasm (5, 26) . As shown by cDNA analysis, the BRLF1 protein (R) is derived from a bicistronic mRNA which also encodes the * Corresponding author. Z protein (25) , suggesting that the regulation of Z and R is tightly linked. The R transactivator, in contrast to Z, cannot disrupt viral latency when transfected and overexpressed in cells (5) .
Several EBV early promoters are transactivated by either Z or R. The genes activated by Z include BMLF1, BMRF1, the BZLF1 gene itself, and the divergent promoter (DR/DL) (1-5, 12, 13, 23, 25, 31, 35) . Z-responsive elements in these promoters have been mapped within 100 base pairs (bp) of the TATA box, and the response elements have included AP-1 (or closely related) binding sites. The R transactivator activates the DR promoter and the BMLF1 promoter (1-3, 5, 12) . The R-responsive regions in both of these promoters reside within upstream enhancer elements, and both of these R-responsive elements contain the same 14-bp sequence motif, CCGTGGAC/GAATGTC. Whether the R transactivator binds to DNA is unknown at present.
In the work described in this paper, we have studied the regulation of the EBV BMRF1 early promoter, EA-D. The BMRF1 gene encodes the early antigen diffuse (EA-D) protein, which is an essential component of the viral DNA polymerase activity (22) . EA-D activity is suppressed in latent infection and reactivated during productive infection (6 (27) . The primer extension products were electrophoresed on a 6% acrylamide-7 M urea gel.
In vitro site-directed mutagenesis. Mutants were made by using the Bio-Rad Muta-Gene phagemid in vitro mutagenesis kit, based on a method described by Kunkel et al. (19, 20 (12) (which contains the primarily R-responsive BMLF1 promoter) or the pEA-CAT plasmid (-331 to + 1), which contains the early EA-D promoter, was cotransfected with 5 p.g of either pEBV-ZIE (which encodes Z), pEBV-RIE (which encodes R), or both transactivators together. CAT assays were performed as described previously (9) . CAT assay results are presented as fold induction over basal levels. In lymphoid cells (Louckes and Jurkat), the combination of R and Z is required for maximal stimulation of the EA-D promoter, whereas R alone is sufficient for maximal stimulation of the BMLF1 construct. In epithelial cells (HeLa and HEp-2), Z alone produces maximal' transactivation of the EA-D promoter, whereas R alone is sufficient for maximal stimulation of the BMLF1 promoter.
Mutants were made by using a synthetic oligonucleotide complementary to the region to be altered except for a limited internal mismatch. For screening possible mutants, synthetic oligonucleotides were created such that in vitro mutations would create a new PvuII restriction site which allows each possible mutant to be analyzed by digestion with restriction endonucleases. Following initial screening, potential mutants were sequenced with the Sequenase 2.0 enzyme sequencing kit (United States Biochemical Corp.) to identify the mutation.
RESULTS
The EA-D promoter is differentially regulated in lymphoid and epithelial-cell types. We have previously reported that the EA-D promoter can be stimulated in both EBV-positive and EBV-negative cell lines by cotransfection with the Z transactivator plasmid (13) . In this study we examined the effects of the Z and R transactivators alone and in combination on EA-D promoter activity in different cell types. Figure  3 illustrates representative CAT assays in which the pEA-CAT plasmid was cotransfected into various cell types with either the pEBV-ZIE plasmid (which encodes BZLF1) or the pEBV-RIE plasmid (which encodes BRLF1), or both transactivators together.
In either B or T lymphoid cell lines (Louckes and Jurkat), the EA-CAT promoter activity was only slightly increased on cotransfection with either Z or R. However, when pEA-CAT was cotransfected with both transactivators together in lymphoid cells, a large stimulatory effect was obtained. This synergistic effect of Z and R together was observed with either the pEBV-ZIE and pEBV-RIE plasmids in combination or the pEBV-RZ plasmid alone, which expresses the bicistronic Z/R mRNA. In contrast, the plasmid pM-CAT, which contains the promoter of the EBV BMLF1 gene and has been previously shown to be primarily R responsive (12) , is transactivated equally well by either R alone or the combination of Z and R in Jurkat cells.
In the epithelial-cell lines HeLa and HEp-2, the Z transactivator alone produced a large stimulatory effect on pEA-CAT activity. As in lymphoid cells, the R transactivator alone produced only a small effect. When both transactivators were cotransfected into epithelial cells, the effect of Z and R together upon EA-CAT activity was no greater than that of Z alone. The pM-CAT plasmid, as expected, was efficiently transactivated by either R alone or the R and Z combination in HeLa cells. These data suggest that the Z transactivator alone is sufficient to activate EA-D promoter activity maximally in epithelial cells. In contrast, both Z and R are required for efficient EA-D promoter transactivation in lymphoid cells.
RNA analysis. Previous studies have shown that both the Z-and R-induced transactivation of reporter gene constructs is associated with a similar increase in steady-state RNA levels (12, 13) . In this study we analyzed the effect of the Z/R transactivator combination on the steady-state level of pEA-CAT RNA in lymphoid cells. In the experiment shown in Fig. 4 a The numbers shown represent the average percent acetylation from four experiments. Ranges are given in parentheses. b The numbers shown represent the average fold increase in CAT activity when each CAT plasmid was cotransfected with either pEBV-ZIE, pEBV-RIE, or pEBV-RZ with respect to the activity with the pHD1013 vector. Ranges (in parentheses) are those from three experiments for pEBV-RIE and four experiments for pEBV-ZIE and pEBV-RZ.
sequences between -265 and -62 were deleted, although the region located between -265 and -214 appeared to play the greatest role in the total transactivation. Neither the intact pEA-CAT plasmid nor any of the 5' deletion mutations were significantly transactivated with the R-gene product alone in the Jurkat cell line.
In HeLa cells, maximum stimulation of the parent, pEA-CAT, occurred with the Z transactivation alone (Fig.  3) . Likewise, the effect of Z and R together on each mutant was no greater than that of Z alone (data not shown). As in lymphoid cells, a significant portion of the Z effect in HeLa cells was lost when the sequences between -265 and -214 were deleted (Table 2 were deleted. In epithelial cells, the 17-bp region between -79 and -62 (which contains a portion of the potential AP-1 binding site) also contributed to Z responsiveness, since the pEA construct (-79 to +1) was 13-fold more responsive to Z than the pEA construct (-62 to +29). The effect of R alone in HeLa cells was too small to be accurately mapped.
Role of the AP-1 consensus site in Z and R transactivation of the EA-D promoter. To better define the role of the AP-1 consensus site in Z-and Z/R-induced transactivation of the EA-D promoter in different cell types, we constructed a series of site-directed mutants of the EA-CAT construct by using in vitro mutagenesis. To facilitate these studies, we transferred the EA-D promoter sequences and CAT gene from the pEA-CAT construct into a Bluescript M13 SK+ phagemid vector to create the construct pEA-BS-CAT. Using the method of Kunkel et al. (19, 20) , the 6 bp defining the AP-1 binding site in pEA-BS-CAT was specifically altered as shown in Table 3 , leaving the rest of the promoter unchanged. In addition, since analysis of the 5' deletion mutants suggested that sequences further upstream from the potential AP-1 site may also contribute to Z/R transactivation, three other site-directed mutants were constructed which each remove potential AP-1-like binding sites lying between -197 and -240. One additional mutant, which alters a sequence (-185 to -198) containing a 10-of-14-bp similarity to the shared R-response sequence region of the DR and BMLF1 enhancers (1) (2) (3) 12) was also constructed. The effects of the Z, R, and Z/R transactivators on these site-directed mutants are shown in Tables 4 and 5 .
The AP-1 site-directed mutation in pEAAAP1-CAT decreased Z-induced transactivation in HeLa cells by more than 20-fold, confirming that the AP-1 consensus site plays a major role in EA-D regulation in epithelial cells. However, in lymphoid cells (Table 5 ), the AP-1 mutation produced little 4-of-8-bp similarity to the consensus AP-1 site. c The mutation AZB4 alters a sequence which shares a 10-of-14-bp similarity with the previously described shared R-response regions in the EBV DR and BMLF1 enhancers (2, 3, 12) . effect on the ability of Z and R together to transactivate the EA-D promoter, suggesting that the ability of R to interact synergistically with Z in lymphoid cells is not mediated by increased Z binding to the consensus AP-1 site. None of the other site-directed mutants significantly affected Z or Z-plus-R transactivation in either cell type.
DISCUSSION
We have demonstrated in these studies that EA-D (BMRF1) promoter regulation by the Z and R IE transactivators is cell type specific and appears to involve different mechanisms. In epithelial cells, the Z gene product efficiently transactivates the promoter for the EA-D early gene, whereas effective transactivation of the same promoter in lymphoid cells requires the addition of the R transactivator. These differences in transactivation efficiency correlate with different mechanisms of transactivation. In epithelial cells, the potential AP-1 binding site, in addition to promoter sequences further upstream (-214 to -265), is required for Z response. In lymphoid cells, the AP-1 site is dispensable for Z-plus-R transactivation, although the upstream regulatory sequences (-214 to -265) are essential. Therefore, the ability of the R and Z transactivators to synergistically activate the EA-D promoter in lymphoid cells appears to involve a mechanism independent of Z binding to the AP-1 site.
The regulation of the EA-D promoter by Z and R is distinct from that of other EBV promoters previously studied. We have previously shown that another EBV promoter, BMLF1, responds to the R transactivator in either (37.2-197.6) a The numbers shown represent the average fold increase in CAT activity when each CAT plasmid was cotransfected with the pEBV-RZ plasmid with respect to the activity with the pHD1013 vector. Ranges are those from two experiments.
EBV-positive or EBV-negative lymphoid and epithelial cells, and mapped the R-response region in this promoter to a 140-bp enhancer element (12) . Several investigators have reported that in addition to R, the BMLF1 promoter can be activated (although to a much lesser extent) by the Z transactivator, and they have mapped the Z-response region to an AP-1 site (1, 12, 30, 35) .
Our studies suggest that the regulation of the BMLF1 and BMRF1 (EA-D) promoters by the Z and R transactivators is clearly different. The BMLF1 promoter is primarily R responsive, and the effect of R and Z together is no greater than that of R alone (at least when levels of R and Z are not limiting) (12) . Furthermore, no tissue specificity in the effects of R or Z on BMLF1 promoter activity has been observed (1, 12) . Unlike the case with BMRF1, in the BMLF1 promoter the R-responsive and Z-responsive regions of the promoter clearly map to separate regions.
Studies involving the EBV divergent promoter (BHLF1 and BHRF1) have shown that the R and Z transactivators are both involved in the regulation of this complex element. The R-responsive region of this promoter element can be clearly mapped to an enhancer region which contains a 14-bp sequence similar to a sequence in the R-responsive enhancer of the BMLF1 promoter (1) (2) (3) 12) . The Z transactivator also activates the BHLF1 promoter. Lieberman et al. (23) (23) . Alternatively, the increased length of RNA leader sequences in the -214/+29 and -62/+29 constructs may inhibit the effect of Z. In either case, the importance of the potential AP-1 binding site (located between -57 and -64) for Z transactivation in epithelial cells was confirmed by sitedirected mutagenesis of the AP-1 site.
Exactly why the Z protein alone is sufficient to activate the R promoter in epithelial cells, yet both the Z and R proteins are required for maximum activation of lymphoid cells, is still speculative. Perhaps there is a cellular factor expressed in epithelial cells that replaces the function of the R protein.
If so, the mechanism of this hypothetical epithelial-cell factor must be different from the mechanism of R, since the AP-1 site is dispensable for the Z-plus-R interaction, but not when Z alone is used in epithelial cells. There may be a factor present in lymphoid cells, but lacking in epithelial cells, that inhibits efficient binding of Z to the AP-1 site. In this case the helper role of R in lymphoid cells might involve binding by Z to alternative upstream binding sites. Alternatively, the effect of Z plus R in lymphoid cells might involve direct EA-D binding by the R protein (with Z providing a helper function in this case). A particularly interesting possibility is that Z and R might act synergistically through protein-protein interactions. Distinguishing between these possibilities will require further protein-DNA binding studies.
The findings presented here with Jurkat and HeLa cells do not necessarily correlate with the regulation of EBV infection in vivo, since neither of these cell types can actually be infected by EBV. It is possible that the differences observed in EA-D promoter regulation in Jurkat cells and HeLa cells are due to differences in the degree of cell differentiation (since EBV tends to be more productive in more differentiated cells) rather than to tissue-specific differences. Nevertheless, these findings may well have biological relevance in EBV infection. The tendency for EBV infection to remain latent in lymphoid cells may relate to the requirement in this cell type for both transactivating proteins, Z and R, to be expressed if transactivation of certain crucial promoters such as EA-D and the DR enhancer element is to occur. Likewise, the ability of Z alone to activate certain promoters in epithelial cells, but not lymphoid cells, may contribute to the relative permissiveness of this cell type for productive viral infection. The requirement for R transactivation (in addition to Z) for activation of certain promoters in lymphoid cells suggests that R function is likely to be crucial in the disruption of viral latency in lymphoid cells. However, whether the R transactivating function is also required for productive infection of epithelial cells remains to be determined.
